藻酸双酯钠局部注射治疗眼睑黄色瘤的临床观察

目的分析观察藻酸双酯钠局部注射治疗眼睑黄色瘤的疗效。方法用藻酸双酯钠局部注射治疗眼睑黄色瘤20例40眼，每日注射1次，10次为一疗程，注射药量视瘤体大小而定，一般0．4～0．8ml，一般治疗1～2个疗程。结果治愈率达95％，未出现明显并发症。结论藻酸双酯钠局部注射治疗眼睑黄色瘤方法简便易行，药物价廉易得，患者无明显痛苦，毒副作用小，疗效可靠。     

藻酸双酯钠治疗眼睑黄色瘤26例

0引言眼睑黄色瘤也称眼睑扁平黄色瘤,多发于眼上睑内眦部,多呈对称性分布,为扁平淡黄色或棕黄色丘疹。大小从几毫米到数厘米,边界清楚,表面光滑,多见于各种高脂血症,但也可见于血脂正常者[1]。我科门诊于2003-11/2005-11,应用藻酸双酯钠注射液皮内注射治疗26例,疗效显著,现报告     

肝素钠皮内注射治疗眼睑黄色瘤疗效分析

目的 观察肝素钠皮内注射治疗眼睑黄色瘤的疗效。方法 对２４６例４９２只眼睑黄色瘤施行肝素钠皮内注射。结果 注射２周后黄色瘤消失３２０眼,注射３～４周后黄色瘤基本消失１２６眼,５～７周后黄色瘤消失４６眼。结论 肝素钠能激活体内脂蛋白酯酶,可使乳糜中的甘油三酯水解,从而降低血脂,使黄色瘤消失。     

肝素钠治疗眼睑黄色瘤的临床观察

黄色瘤是脂质代谢障碍的皮肤病,好发于眼睑称睑黄色瘤。本病影响美观,既往手术切除,非手术疗效不满意。我院于１９９１年始应用肝素局部注射６０例,１０２只眼,１１０处黄色瘤,取得良好的效果,治愈率达１００％。肝素可改善睑黄色瘤局部的微循环,消除了局部组织内脂肪,使真皮内的黄瘤细胞脂肪清除,使之恢复到正常皮肤。本方法治疗睑黄色瘤方便,简单,是一种疗铲好的非手术疗法。     

低分子量肝素局部注射治疗眼睑黄色瘤

肝素钠注射治疗眼睑黄色瘤在许多患者取得较满意的效果。我们对一些黄色瘤患者使用低分子量肝素钠 (商品名海普宁 ,江苏江山制药厂生产 ,剂型 2 5 0 0U/ 0 5mL)局部皮内注射 ,获得了比肝素钠更理想的治疗效果 ,现报告如下。1　资料与方法1.1　一般资料　临床诊断为眼睑黄色瘤患     

高频电离子疗法治疗眼睑黄色瘤

目的 探讨高频电离子疗法在眼睑黄色瘤治疗中的意义。方法 运用高频电离子治疗仪对71例127眼睑黄色瘤进行逐层烧灼，观察术中及术后眼睑局部组织的一系列变化，随访6－9月。结果 治愈63例（88.73%)，显效6例（8.45%)复发2例（2.82%)。所有病例均于术后5－10天创面结痂自行脱落，皮肤粉红色在3月左右与周围皮肤变为一致，无感染，无瘢痕畸形出现。结论 高频电离子疗法用于治疗眼睑黄色瘤可减少患者对手术的恐惧和经济负担，无并发症，效果理想。     

先天性黄色瘤1例

先天性黄色瘤１例泰山医学院附属医院眼科程普斋，尹玉凤眼睑黄色瘤是眼睑部位皮肤常见的良性肿瘤，多见老年女性，发生在４个月婴儿实属少见，现报告如下。患儿陈×女４个月右上眼睑长一肿物４个月，自患儿出生后即见其右眼上睑眉弓处有一绿豆粒大小黄色肿物，略高出皮肤...     

平阳霉素治疗眼睑黄色瘤30例临床观察

目的 观察应用平阳霉素注射治疗眼睑部黄色瘤的疗效。方法 采用天津市河北制药厂生产的8mg／支平阳霉素粉剂加生理盐水2ml溶解后。抽入1ml皮试注射器内，用41／2号或5号针头，消毒眼睑皮肤后，注入黄色瘤体内并超越瘤体2mm，15天后如有残余瘤体未消，可重注1次。结果 本组治疗共30例，男3例，女27例；1次注射治愈者23例，2次治愈者7例；经随访观察6—24个月无复发。结论 应用平阳霉素注射治疗眼睑黄色素瘤治愈率高，具有操作简便、安全可靠、剂量小、疗效快、副作用轻等优点，是目前治疗眼睑黄色瘤的一种好办法。     

Operative Treatment of Large Periocular Xanthelasma

Purpose: To present our experience in operative treatment of large periocular xanthelasma. Methods: Sixty-three patients with large periocular xanthelasma were operatively treated in our department. Ipsilateral and/or contralateral lid skin grafts harvested by blepharoplasty, alone or in combination with local flaps, were used. Forty patients (64%) had enough skin to graft the defect after primary xanthelasma removal. In 10 patients, additional local flaps were used: modified rhomboid flap in six patients, local advancement flap in two, and bi-lobed flap in two patients. In three patients (5%), a sequential approach was applied since xanthelasma were too large to be completely removed in a single-step excision. No serious complications were shown. Results: Patients were followed from 6 months to 8 years. Five patients (8%) returned with recurrences 3–8 years after primary excision. Conclusions: In lack of the setting for xanthelasma laser treatment, operative approach of a single-step or sequential excision using lid skin graft combined with local flaps proved its value for large periocular xanthelasma.     

改良睑黄色瘤切除手术的观察

目的 观察改良睑黄色瘤切除术的应用效果。方法 选择病灶〈10mm以下的瘤体为手术观察对象，共22例（38眼）。按超皮损病灶边界1mm设计切口缘，梭形切除病灶，深达真皮层，在显微镜下清除皮下组织及切缘脂肪组织，松解切口边缘皮肤，连续皮内缝合切口。另外，酌情行上睑松弛矫治术。结果 失访2例（2眼），随访20例（36眼）6—12个月，未见黄色瘤复发，切口平整，痕迹隐约。结论 采用改良睑黄色瘤切除术更会增强眼睑形态美感。     

Central Serous Chorioretinopathy Associated with Topical Latanoprost Therapy

Purpose: To report a case of central serous chorioretinopathy (CSC) as a possible complication of latanoprost treatment.

Methods: A 65-year-old woman presented with a 1-week history of blurred vision and metamorphopsia in her right eye. She was previously diagnosed with unilateral glaucoma, and treatment was initiated with topical latanoprost 0.005% for the right eye. The symptoms occurred 1 month after initiation of glaucoma treatment.

Results: Visual acuity (VA) of the patient had reduced to 20/50 in right eye. Fluorescein angiography revealed a focal RPE leak near to the fovea with neurosensory detachment due to CSC, which was confirmed by optical coherence tomography. After cessation of the therapy, her clinical and morphological status improved spontaneously. The neurosensory detachment resolved almost completely and VA improved to 20/20 simultaneously.

Conclusions: The authors report the first case of CSC associated with latonoprost therapy. This case demonstrates that topical latanoprost may lead to the development of CSC.     

硫酸镍对Wistar大鼠晶状体的损伤及芪归解毒汤对其保护作用的研究

目的 探讨硫酸镍对Wistar大鼠晶状体的损伤情况及芪归解毒汤对其保护作用.方法 选用出生7～14d的Wistar大鼠,随机分为芪归解毒汤预防组、障眼明预防组、硫酸镍组、空白对照组,每组15只.芪归解毒汤预防组:芪归解毒汤按1 ml/100 g给药灌胃7d后,再同时芪归解毒汤灌胃每天2次和硫酸镍溶液皮下注射每天1次,连续45 d;障眼明预防组:障眼明溶液按0.23 g/kg给药灌胃7d后,再同时用障眼明溶液灌胃每天2次和硫酸镍溶液皮下注射每天1次,连续45d;硫酸镍对照组:用2 mg/ml的硫酸镍溶液按15 mg/kg的剂量连续皮下注射45 d;空白组:Wistar大鼠不做任何处理,同等条件下正常饲养45 d.45d后双盲法在裂隙灯显微镜下参照LOCSⅢ评价Wistar大鼠晶状体的浑浊程度.最后处死大鼠,取下完整晶状体,置于10％福尔马林溶液中4℃保存,用原子吸收分光光度计测定镍含量.用SPSS 16.0软件进行单因素方差分析或秩和检验.结果 晶状体浑浊度观察:在晶状体P区域中,硫酸镍组晶状体浑浊指数得分高于芪归解毒汤预防组、障眼明预防组及对照组,差异有统计学意义(F=35.28,P＜0.05);在晶状体N区域中,硫酸镍组晶状体浑浊指数得分高于芪归解毒汤预防组、障眼明预防组及空白对照组,差异有统计学意义(F=78.64,P＜0.05).在晶状体A、C两区域,晶状体浑浊指数得分各组之间差异无统计学意义(F=0.173,P=0.914;F=0.364,P=0.779);在晶状体A+P区域上,硫酸镍组晶状体浑浊指数得分高于芪归解毒汤预防组、障眼明预防组及空白对照组,差异有统计学意义(F=30.24,P＜0.05).晶状体A+C+N+P4个区域浑浊指数得分总和分析,硫酸镍组晶状体浑浊指数得分高于芪归解毒汤预防组、障眼明预防组及空白对照组,差异均有统计学意义(F =38.14,P＜0.05);硫酸镍含量测定:硫酸镍组高于空白对照组(Z=-3.100,P＜0.05);芪归解毒汤预防组低于硫酸镍组(Z=-3.920,P＜0.05);障眼明预防组比较,差异无统计学意义(F=0.035,P＞0.05).结论 硫酸镍皮下注射能对Wistar大鼠晶状体造成一定的损伤,芪归解毒汤能有效减轻硫酸镍对Wistar大鼠晶状体的损伤.     

Impact of Lycium Barbarum Polysaccharide and Danshensu on vascular endothelial growth factor in the process of retinal neovascularization of rabbit

AIM:To discuss the impact of Lycium Barbarum Polysaccharide (LBP) and Danshensu purified from Traditional Chinese Medicine (TCM) on vascular endothelial growth factor (VEGF) of rabbits with retinal neovascularization.METHODS:Forty rabbits were divided into normal control group, model control group, LBP group and Danshensu group. Animals in the normal control group were fed in the normal oxygen environment. Animals in the other three groups were put into the environment with 70% oxygen for 5 days in order to build the model of oxygen-induced vascular proliferation retinopathy. And then different TCM extract was injected into the abdominal cavities of these annimals. After 7 days, the VEGF content of in the serum of rabbit was measured by double antibody sandwich method.RESULTS:Data analysis indicated that VEGF content was as follows:Danshensu group was lower than model control group (12.92±3.84ng/L vs 19.32±4.15ng/L, P<0.05); LBP group and normal control group were lower than model control group (12.92±3.84ng/L, 9.26±1.61ng/L vs 19.32±4.15ng/L, P<0.01); total blood viscosity, plasma viscosity, cholesterol content, fibrinogen content and triacylglycerol content after peritoneal injection of LBP and Danshensu were obviously lower than before injection.CONCLUSION:TCM extract-LBP and Danshensu can prominently reduce the content of VEGF in the process of vascular proliferative retinopathy of rabbit; can prevent the occurrence of retinal microvascular disease by improving partial oxygen-deficient environment or affecting all kinds of new growth factor.     

Comparison of Subtenon Triamcinolone Acetonide Injection with Topical Nepafenac for the Treatment of Pseudophakic Cystoid Macular Edema

Purpose: To compare the efficacy and safety of subtenon triamcinolone acetonide (TA) injection with topical nepafenac 0.1% for the treatment of pseudophakic cystoid macular edema (CME).

Methods: In this prospective study, the TA group comprised 24 eyes and the nepafenac group 24 eyes. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure measurements, and slit-lamp fundoscopy were performed in all subjects at baseline, 1, 2, 3, and 6 months.

Results: Changes in BCVA and CRT over four follow-up visits were statistically significant (p<0.001). The mean CRT decreased from 513.3 to 318.9 μm in the TA group and from 483.7 to 278.0 μm in the nepafenac group. This reduction was statistically significant (p<0.001 for both groups).

Conclusions: Our visual and OCT results suggest that both treatment modalities are effective with few side-effects. However, nepafenac is more efficacious than subtenon TA in terms of visual gain and its correlation with the reduction in CRT.     

眼睑黄色瘤与高胆固醇血症中遗传因素的相关性研究

目的:探讨眼睑黄色瘤(XP)与高胆固醇血症中遗传因素的相关性,为揭示其发病机制提供依据。方法:选取2019-11/2021-01在佛山市三水区人民医院眼科就诊的XP患者29例,抽取外周静脉血,通过二代测序(NGS)技术检测患者的基因突变情况,同时分析患者的血脂情况。结果:纳入的XP患者中有21例检出基因突变,其中13例为高胆固醇血症患者,8例为正常胆固醇患者,发生突变的基因包括STAP1、APOB、LDLRAP1、LDLR、PCSK9和APOE,基因突变类型包括3-UTR变异、框内缺失、错义变异、5-UTR变异、同义突变、内含子突变、可变剪接体变异、非编码转录外显子突变和非编码转录突变。结论:高胆固醇血症的遗传因素与XP疾病之间有一定的相关性。     

Topical Glaucoma Therapy Is Associated With Alterations of the Ocular Surface Microbiome

PurposeTo investigate the ocular surface microbiome of patients with unilateral or asymmetric glaucoma being treated with topical ophthalmic medications in one eye and to determine whether microbial community changes were related to measures of ocular surface disease.MethodsV3-V4 16S rRNA sequencing was conducted on ocular surface swabs collected from both eyes of 17 subjects: 10 patients with asymmetric/unilateral glaucoma using topical glaucoma therapy on only one eye and seven age-matched, healthy controls with no history of ocular disease or eyedrop use. Samples were categorized into three groups: patients’ glaucomatous eye treated with eyedrops, patients’ contralateral eye without eyedrops, and healthy control eyes. Comparisons were made for microbial diversity and composition, with differences in composition tested for association with ocular surface disease measures including tear meniscus height, tear break-up time, and Dry Eye Questionnaire.ResultsSamples obtained from the patients’ treated and untreated eyes both had significantly greater alpha-diversity and relative abundance of gram-negative organisms compared to healthy controls. The microbial composition of patient eyes was associated with decreased tear meniscus height and tear break-up time, whereas metagenomic predictions, based on 16S rRNA data, suggested increased synthesis of lipopolysaccharide.ConclusionsThe ocular surface microbiome of patients taking unilateral preserved glaucoma drops is characterized by a highly diverse array of gram-negative bacteria that is significantly different from the predominantly gram-positive microbes detected on healthy control eyes. These compositional differences were associated with decreased tear film measures and distinct inferred protein synthesis pathways, suggesting a potential link between microbial alterations and ocular surface inflammation.     

眼睑黄色瘤巨噬细胞清道夫受体1单核苷酸多态性研究

目的：探讨眼睑黄色瘤与巨噬细胞清道夫受体1(MSR1)基因单核苷酸多态性(SNP)的相关性。

方法：分别抽取20例眼睑黄色瘤患者和20例健康者的空腹外周静脉血,应用Sanger测序方法进行MSR1基因型SNP检测,眼睑黄色瘤患者同时进行血脂、α-脂蛋白水平、颈动脉彩超等检查。

结果：眼睑黄色瘤患者和健康人MSR1基因型SNP分布无显著差异,但部分合并颈动脉硬化和高血脂症的患者MSR1外显子区域S2-SNP1、S5-SNP2、S5-SNP4位点发生纯合突变。

结论：眼睑黄色瘤与抗动脉粥样硬化受体MSR1基因型SNP具有相关性。     

Efficacy of 2% Lidocaine Injection as a Topical Agent in Cataract Surgery

Purpose: To determine whether 2％ Lidocaine injection is an effective topical anesthetic agent for non-phaco small incision cataract surgery.Setting: Charity eye clinic supported by Hellen Keller International.Methods: One hundred and twenty-five consecutive cataract surgery patients received topical anesthesia with 2％ Lidoeaine injection solution just 1 and 0.5 minutes prior to non-phaeo small incision cataract extraction and intraocular lens implantation. Each patient was asked about pain or pressure sensation during the operation.Results: The surgeon felt ease in the operations. Many patients (93/125) were comfort during the whole surgery. Only 9 patients'score was above level 3, mostly complained during the nucleus extraction; Among those whose score was level 1～2, 82.6％(19/23) claimed discomfort at middle of the operation (nucleus extraction) or the beginning (creating the conjunctival flap).Conclusion: Lidocaine injection solution(2％) was an effective topical anesthesia agent in cataract surge